Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome assembly chaperone 4 (PAC4) is one of five dedicated chaperones required for the orderly biogenesis of the 20S core particle of the eukaryotic proteasome. PAC4 binds and temporarily associates with other chaperones (notably PAC3, forming a heterodimer), facilitating the arrangement of the seven distinct α subunits into a correct α-ring configuration during early proteasome assembly. After this, PAC4 dissociates as β subunits are incorporated. Understanding PAC4’s structure and function is ongoing, but it is emerging as a potential drug target for anticancer therapies aiming to inhibit proteasome assembly specifically in cancer cells, which demand increased protein degradation capacity.
Inhibition of assembly chaperone function, thereby blocking the formation of the proteasome core particle and reducing proteasome activity in cells (especially cancer)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome assembly chaperone 4 (PAC4).